Technology | Embolization devices | August 17, 2015

Merit Medical Receives FDA Clearance Expanding Indication for QuadraSphere Microspheres

Applications for embolic agent now include malignant hepatoma

Merit Medical, QuadraSphere Microspheres, FDA approval, expanding indication, hepatoma

Image courtesy of Merit Medical Systems Inc.


August 17, 2015 — Merit Medical Systems Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) expanding indication for QuadraSphere Microspheres to include the embolization of hepatoma. Malignant hepatoma, also known as hepatocellular carcinoma (HCC), is the sixth most common cancer and the third leading cause of cancer deaths worldwide. QuadraSphere Microspheres are precisely calibrated and designed to offer controlled, targeted embolization, treating HCC by stopping blood flow to the tumors. 

For more information: www.merit.com


Additional Content

News | Embolization devices

Aug. 20, 2026 – The novel, radiopaque, polymer-based embolic coil from Embolization, Inc. has now surpassed 125 implants ...

Home August 20, 2026
Home
News | Embolization devices

June 8, 2026 – Embolization, Inc. will present its novel embolization coil, using proprietary shape-memory biocompatible ...

Home June 08, 2026
Home
News | Embolization devices

June 5, 2025 – Penumbra, Inc. has announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby ...

Home June 05, 2025
Home
News | Embolization devices

July 28, 2022 — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral ...

Home July 28, 2022
Home
News | Embolization devices
March 31, 2022 – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral ...
Home March 31, 2022
Home
Subscribe Now